CPCs represent a compelling and commercially viable therapy.
Although inherited retinal diseases are rare, they collectively represent a large unmet medical need. Age-related macular degeneration, our ultimate target of therapy, is not rare.
CPC treatment has the potential to generate $1.8B in revenue.
Commercialization for the treatment of IRD (year 4) will reach the potential to generate revenues of >$10M/yr.
These calculations do not include previously diagnosed patients with AMD or IRD.